Indication intelligence, analysis and sector perception

Precigen (PGEN) closes 17.25 M share offering at $7.50

January 26, 2021 5:43pm

PGEN closed down -$0.76 or -8.60% to $8.14

Including a full execise 2.25 M share option

Proceeds from the offering, are expected to be approximately $129.5 million, before deducting expenses

PGEN has closed an underwritten public offering of shares of its common stock.

Wells Fargo Securities and Stifel are acting as joint book-running managers for the offering with JMP Securities acting as lead co-manager and H.C. Wainwright & Co. acting as co-manager.

The Bottom Line:

A 52-week change of 59.49%,
A 52-week high of $11.10 and a low of $1.26;
A 50-day moving average of 9.05 with a 200-day 5.93;
Shares outstanding of 185.54 M and a float of 73.28 M;
Held by institutions: 65.99%;
Cash of $113.1 M and debt of $219.13 M

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 57 min ago
RegMed Investors (RMi) Closing Bell: sector ascended after being under pressure

3 hours 12 min ago
RegMed Investors (RMi): Happy soon to be New Year – 2025

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.